6.3 Peripheral Device Selection Criteria
Key Takeaways
Select the least invasive peripheral device that safely meets therapy duration, infusate characteristics (osmolarity, pH, vesicant/irritant properties), and administration pattern (intermittent vs continuous).
Preserve vessel health with stepwise escalation: short PIV → long peripheral/UGPIV → midline → central access only when therapy or duration demands it.
Never choose a short PIV or midline for continuous vesicants or for extreme osmolarity/pH/TPN needs that require confirmed central tip location.
Avoid using the antecubital fossa for long-term dwell when better forearm options exist; avoid ventral wrist sites due to nerve injury risk.
Reassess device necessity daily—remove peripheral access that is no longer indicated to cut infection, phlebitis, and thrombosis risk.
Selection as a safety algorithm
CRNI Access Devices items rarely ask you to name a brand. They ask you to choose the right class of device for a therapy story. Section 6.3 integrates short PIV, long peripheral, and midline decision rules into one practical framework aligned with INS-minded vessel health preservation.
Quick Answer: Choose the lowest-risk, least invasive device that still matches (1) duration, (2) osmolarity/pH, (3) vesicant/irritant properties, and (4) intermittent vs continuous delivery. Escalate stepwise—short PIV → long peripheral/UGPIV → midline → CVAD—only as therapy demands. Midlines are not central. Continuous vesicants and many hyperosmolar/extreme pH/TPN therapies need central tips. Prefer forearm over AC for dwell; avoid ventral wrist.
The four therapy drivers
1. Duration of therapy
| Expected duration | Typical peripheral pathway thinking |
|---|---|
| Hours to a few days | Short PIV first-line if veins adequate |
| Several days with difficult veins | Long peripheral / UGPIV or early midline consideration |
| Days to weeks, peripheral-compatible | Midline often considered if short PIVs inadequate |
| Weeks to months, complex/central chemistry | Plan CVAD (PICC, tunneled, port) rather than serial midlines that do not fix chemistry limits |
Duration alone never overrides chemistry. A one-day continuous vesicant still needs an appropriate device class.
2. Osmolarity
Hyperosmolar infusions draw fluid from endothelial cells and inflame peripheral veins. Standards and drug references set thresholds and product-specific guidance for peripheral versus central administration. Exam principle: as osmolarity rises into ranges associated with high peripheral vein injury risk—especially for continuous infusion—central access becomes the safer default. Do not “stretch” a short PIV or midline to deliver PN or other highly hyperosmolar admixtures that policy assigns to central tips.
3. pH (acidity/alkalinity)
Extreme acidic or alkaline infusates chemically injure the intima. Peripheral veins tolerate a narrower chemical window than high-flow central veins. When references label a drug as requiring central administration due to pH, device selection follows the label/standards, not bedside convenience.
4. Vesicant and irritant properties
| Classification | Clinical concern | Device implication |
|---|---|---|
| Irritant | Pain/phlebitis along vein | May still be peripheral if policy allows; monitor closely; consider larger veins/central if poorly tolerated |
| Vesicant | Tissue necrosis if extravasated | Continuous vesicant → central access; do not use midline/short PIV as a loophole |
| Non-vesicant, peripheral-compatible | Standard infiltration risk | Short PIV, long peripheral, or midline by duration/veins |
Intermittent vs continuous: Continuous exposure multiplies chemical injury time and extravasation detection urgency. Intermittent dosing may be manageable peripherally for some agents under protocol; continuous vesicant infusion is a hard stop against midline/short PIV on exam items.
Stepwise escalation and vessel health preservation
Think of peripheral veins as a non-renewable resource for many chronically ill patients.
Escalation ladder (conceptual)
- Is IV therapy required at all? Prefer oral/NG/alternative routes when clinically equal.
- Short PIV in the best available forearm vein with smallest adequate gauge.
- Optimize short PIV success: warmth, proper lighting, expert inserter, limited attempts, vein visualization tools.
- Long peripheral / UGPIV for deeper peripheral targets when short PIVs fail but therapy remains peripheral-compatible.
- Midline for intermediate dwell peripheral-compatible therapy when repeated peripheral restarts harm the patient or vessels.
- CVAD when therapy chemistry, duration, or monitoring needs require central tip location—or when peripheral options are exhausted and still indicated.
Vessel preservation tactics
- Limit unsuccessful attempts; escalate skill level early (two-attempt culture with specialist referral as policy defines).
- Avoid dominant arm when possible if it does not compromise the better vein.
- Protect fistula arms, post-mastectomy/node-dissection arms, and infected limbs.
- Do not place “just in case” IVs without indication in vulnerable patients.
- Remove idle catheters promptly—every unnecessary day of dwell is avoidable risk.
- Document vein condition over time so the next clinician does not blindly re-stick phlebitic cords.
Matching device to scenario (decision table)
| Clinical picture | Prefer |
|---|---|
| Single bolus, good forearm vein, non-vesicant | Short PIV |
| 48-hour fluids/antibiotics, easy veins | Short PIV; clinically indicated removal |
| Difficult superficial veins, peripheral-compatible meds for several days | UGPIV / long peripheral |
| 10–14 days peripheral-compatible intermittent antibiotics, failed short PIVs | Midline candidate |
| Continuous vesicant chemotherapy | CVAD (not short PIV, not midline) |
| Hyperosmolar TPN requiring central admin | CVAD |
| Weeks of complex multi-therapy including central-only drugs | CVAD plan early |
| Easy AC stick in a patient needing 5-day continuous non-vesicant infusion | Seek forearm site instead of AC long dwell |
Site selection criteria within peripheral options
Even after choosing “short PIV,” site quality changes outcomes:
| Prefer | Avoid / minimize for dwell |
|---|---|
| Forearm straight veins | Antecubital fossa for multi-day continuous therapy |
| Areas away from flexion | Ventral wrist (nerve injury) |
| Intact skin, non-infected | Areas of phlebitis, infiltration, hematoma, burns |
| Upper extremity in adults | Routine lower extremity adult access |
| Adequate vein diameter for gauge | Fragile vein with oversized catheter |
AC fossa exam trap: The median cubital vein is large and seductive for first-stick success, but joint motion makes it a poor long-term infusion site. Acceptable for emergencies, short procedures, or when no alternative exists—not the default multi-day continuous site.
Integrating ultrasound and specialist teams
Ultrasound is a selection enabler, not a device class:
- UGPIV can make a short or long peripheral succeed without escalating to midline.
- Ultrasound for midline/PICC still requires correct length and tip target for the intended device.
- Vascular access teams improve first-stick success and appropriate escalation—use them when available rather than exhausting every distal vein.
Risk–benefit communication
Device selection includes informed discussion:
- Why this device class matches the ordered therapy
- Alternatives (including oral switch if appropriate)
- Risks: phlebitis, infiltration/extravasation, thrombosis, infection, insertion discomfort
- Patient preferences (arm choice, fear of needles, home care capability for midline/PICC)
Document the rationale when choosing midline over serial PIVs or when escalating to PICC because of vesicant/osmolarity needs.
Daily reassessment checklist
Use this mental checklist each shift:
- Is the catheter still indicated?
- Is the therapy still compatible with this device class?
- Is the site healthy (no infiltration, phlebitis meeting removal criteria, leakage, purulence)?
- Is the device functional (flush, blood return as expected, no unresolved occlusion)?
- Would a different device now better match an evolving plan (e.g., new vesicant order)?
If a patient starts on short PIV antibiotics and the plan changes to continuous vesicant therapy, re-select the device—do not keep the short PIV because “access is already there.”
Putting it together: two full vignettes
Vignette 1: 45-year-old with cellulitis needs 7 days of intermittent peripheral-compatible IV antibiotics, then oral step-down. Forearm vein available. Select short PIV, educate on site care, assess every shift, remove when converted to oral or if complications occur. No midline required solely for a week if peripheral access is reliable.
Vignette 2: 68-year-old with poor superficial veins needs 12 days of peripheral-compatible IV antibiotics; three short PIV failures overnight; no vesicant; no PN. Ultrasound shows upper-arm vein suitable for midline. Midline is reasonable to preserve vessels and complete therapy. If orders later add continuous vesicant or central-only PN, escalate to PICC/other CVAD—do not stretch the midline.
High-yield exam traps (selection-focused)
- Calling a midline a central line and using it for central-only therapies
- Infusing continuous vesicants via midline or short PIV
- Using the AC fossa long-term because insertion was easy
- Skipping stepwise thinking and placing a PICC for every multi-day antibiotic without evaluating peripheral suitability
- Leaving idle peripheral devices in place “for convenience”
- Choosing gauge/site by habit instead of therapy and vessel health
Summary decision mantra
Right drug → right duration → right vein → right device tip location → right time to remove. If any element changes, re-run the algorithm. That mantra is the clinical and CRNI selection standard for peripheral venous access devices.
Which factor set should drive peripheral device selection most directly?
Nurse shift length and supply room inventory only
Patient preference for the largest possible catheter regardless of vein size
Always choosing a midline first to avoid any future restarts
Therapy duration, osmolarity, pH, vesicant/irritant properties, and intermittent versus continuous administration
A patient will receive continuous vesicant chemotherapy. Which access plan is appropriate?
Short PIV in the antecubital fossa changed every 24 hours
Midline catheter because it is longer than a short PIV
Central venous access device with appropriate tip confirmation for central therapy
Long peripheral catheter in the hand for patient mobility
Which example best demonstrates vessel-health-preserving stepwise escalation?
Use a short PIV when suitable; escalate to UGPIV/long peripheral or midline for intermediate peripheral-compatible needs; reserve CVADs for central therapy requirements or true peripheral failure
Place a PICC on arrival for every patient who might need any IV medication
Attempt unlimited short PIV sticks for two days before considering ultrasound or specialist help
Start with a midline for single-dose non-vesicant antiemetic administration
Why is the antecubital fossa generally a poor choice for multi-day continuous peripheral infusion when forearm veins are available?
AC veins cannot accept any IV catheter larger than 24 gauge
Joint motion at the AC fossa increases mechanical phlebitis, kinking, and dislodgement risk during long dwell
Forearm veins are always larger than AC veins in every adult
INS standards forbid any use of the AC fossa even for emergencies
Sections you finish are checked off in the contents.